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Basic hematological indices, such as platelets count (PLT), platelet distribution width (PDW), mean platelet volume (MPV), and platelet-
crit (PCT), are readily accessible and commonly tested indicators. As platelets play a significant role in many physiological and patho-
logical pathways, the abnormalities in these indices inference about irregularities within the organism, such as homeostatic disorders 
or inflammation. Recent studies revealed a significant impact of MPV on the course and prediction in different types of neoplasms. This 
review summarizes the most important studies on the impact of MPV levels on outcome and prognosis in different types of cancer 
conducted in recent years. MPV levels have a significant impact on the length of progression-free survival (PFS) and overall survival (OS) 
in many types of solid tumors, such as colorectal carcinoma, gastric cancer, pancreatic cancer, esophageal cancer, non-small cell lung 
cancer, breast cancer, and thyroid cancer. They also affect the prognosis in some lymphoproliferative diseases, such as diffuse large B-cell 
lymphoma, acute lymphoblastic leukemia, or primary and secondary myelofibrosis.
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Introduction
Basic hematological indices, such as platelets count (PLT), platelet 
distribution width (PDW), mean platelet volume (MPV), and plateletcrit 
(PCT), are readily accessible and commonly tested indicators. As 
platelets play a significant role in many physiological and pathological 
pathways, the abnormalities in these indices inference with homeostatic 
disorders or inflammation. As for oncological process, the deviation 
from the norm in platelet parameters was first described in 1872, when 
Leopold Riess observed increased number of thrombocytes in patients 
with carcinoma [1]. In the next years, these findings were confirmed 
and complemented. The abnormalities in platelet indices turned out 
not only to be a marker of the neoplastic process but also to correlate 
with the severity of the disease. There are many studies confirming the 
correlation between the PLT and the survival time in cancer. Increased 
amount of thrombocytes was described to have a negative impact in 
common cancer entities including breast, lung, colon, esophageal, 
gastric, renal transitional cell, endometrial and ovarian cancers, as well 
as melanoma and glioblastoma [2–7]
Therefore, other platelet indices, including MPV, were considered as 
potential prognosis-affecting factors. MPV is a machine-calculated 
measurement of the average size of platelets found in the blood. It 
reflects the platelet production in bone marrow or platelet destruction 
problems [8]. Recent studies revealed a significant impact of MPV 
on the course and prediction in different types of neoplasms. This is 
particularly interesting in the context of the potential use of a relatively 
cheap, high reproducible, and high applicable laboratory test, such as 
complete blood count, as a prognostic factor in patients with cancer. 
The following work summarizes the current knowledge about the 
prognostic value of MPV in different types of cancer, as well as in 
prediction of post-chemotherapy complications.
Prognostic value of MPV in solid tumors
Recent studies show a correlation between MPV values and the 
prognosis in gastrointestinal tumors. In colorectal carcinoma, the MPV 
level is significantly higher than in patients with colorectal adenoma or 
healthy participants. There is a significant correlation between MPV 
and vascular invasion [9]. Furthermore, in patients with metastatic 
colorectal cancer, the MPV level is significantly higher compared to 
those with no metastasis. Interestingly, patients with lower levels of 
MPV have a better response to bevacizumab-combined chemotherapy 
[10]. The platelet indices were also evaluated as a potential biomarker 
for colorectal carcinoma; however, MPV showed no significant 
correlation with cancer antigens, such as carcinoembryonic antigen 
(CEA) or Ca19.9. In this matter, PLT seems to be more useful, while the 
results suggested that combined detection of PCT and CEA performs 
better than the detection of CEA alone [9].
Likewise, elevated levels of MPV are observed in gastric cancer patients. 
The study of Kilincalp et al. [11] revealed significantly higher MPV 
levels in preoperative patients compared with healthy subjects (8.31 
vs. 7.85 fL; p: 0.007). Surgical tumor resection resulted in a significant 
* Corresponding author: Krzysztof Giannopoulos, Department of Hematology, St. John's Cancer Center, dr K. Jaczewskiego 7 Street, Lublin, Poland; phone: 48 81 4541222; 
e-mail: krzysztof.giannopoulos@gmail.com
155
A c t a  H a e m a t o l o g i c a  P o l o n i c a
decrease of MPV levels. The authors suggest that MPV may be 
used in the diagnosis of gastric cancer patients, independently of the 
clinical stage. The other study showed that in patients with this type 
of neoplasm, a low baseline MPV level is correlated with reduced 
number of metastases [12]. Interestingly, this study also proved the 
link between MPV level and the effectiveness of chemotherapy. 
Patients characterized by the lower baseline level of MPV had a 
better response to chemotherapy. Also individuals whose MPV level 
decreased after first-line chemotherapy had improved response, 
compared to those remaining in the high MPV-level group. The 
influence of MPV on the prognosis was also significant. The median 
overall survival (OS) of the high MPV level group was 9 months, 
whereas for the low MPV-level group – 15.5 months (p < 0.001). 
Progression-free survival (PFS) was respectively 3 and 6 months 
(p < 0.001). In conclusion, the authors suggested that MPV may be 
used in the prediction of chemotherapy response and the follow-up 
of gastric cancer.
The MPV value helps in differential diagnosis of nonfunctional 
pancreatic neuroendocrine tumors (PNET) from pancreatic 
adenocarcinomas. The preoperative median MPV levels are 
significantly lower in patients with PNET (median = 7.8 fL) than in 
patients with pancreatic adenocarcinomas (8.6 fL, p = 0.014) [13]. 
Furthermore, the high level of MPV corresponds to the worse 
course of the disease in pancreatic cancer. Study of Lembeck et al. 
[14] showed that patients with high MPV were more likely to have 
high-grade G3/4 tumors (p = 0.004). Moreover, they had lower 
average PLT, higher average bilirubin levels, and higher CRP levels. 
In multivariable analysis, the adverse association between large 
platelets and a higher risk-of-death prevailed in metastatic stage 
IV patients, but not in patients with early/locally advanced disease 
[14]. Furthermore, in patients with pancreatic ductal adenocarcinoma 
(PDAC), a large platelet volume is associated with high-grade 
G3/4 tumors (p = 0.004) and worse OS in patients with metastatic 
disease in univariable analysis (p = 0.005). Multivariable analysis of 
metastatic PDAC patients showed the adverse association between 
large platelets and a higher risk-of-death prevailed (p = 0.02) [14].
In the other paper, Zhang et al. [15] identified that prolonged 
prothrombin time (PT), high fibrinogen (FBG), and high MPV were 
independent prognostic factors for poor OS in advanced pancreatic 
cancer (PT > 11.3 s, p = 0.009; FBG > 2.5 g/L, p = 0.011; MPV > 12.2 
fL, p = 0.005). They performed univariate and multivariate analysis of 
320 patients using Cox proportional hazards regression, respectively. 
In addition, they proposed a novel scoring system based on PT, 
FBG, and MPV to predict the prognosis of patients with advanced 
pancreatic cancer (prognostic value in both stage III (p < 0.001) and 
stage IV (p = 0.036) patients), which might be used to evaluate the 
prognosis of patients with advanced pancreatic cancer.
Otherwise, opposite dependence occurs in the case of esophageal 
cancer. Survival analysis revealed that both the disease-free survival 
(DFS) and OS in the higher MPV group (MPV > 7.4 fL) are significantly 
longer than those in the low MPV group (DFS p < 0.001; OS p = 
0.003). In addition, MPV has been identified as an independent poor 
prognostic factor for OS [16].
Reduced MPV is associated with shorter survival in other cancer 
as well. Studies by two independent research groups show that in 
renal cancer, worse prognosis is associated with the presence of low 
MPV levels [17, 18]. Yun et al. [17] revealed that lower MPV was 
associated with poorer prognosis histology types, more advanced 
T classification, worse Urinary Incontinence Severity Score (UISS), 
and Mayo clinic stage, size, grade, and necrosis score (SSIGN) 
category. Moreover, patients with low MPV levels had worse 
5-year OS (50.8% vs. 75.9%) than those with high MPV levels (p 
< 0.001). The study of Seles et al. [18] confirmed the results on a 
larger group of patients. Further, the study showed that small platelet 
volume was associated with large tumors (p = 0.043), sarcomatoid 
components (p < 0.0001), histologic tumor necrosis (p = 0.044), and 
vascular invasion (p = 0.022). Decreased MPV was associated with 
an increased risk of death-from-renal cell carcinoma (RCC), while, 
the 10-year cumulative incidence of death-from-RCC was 13.1% in 
patients with low MPV levels and 6.2% in opposite group. A similar 
correlation exists in other cancer of the urinary system. In muscle-
invasive bladder cancer decreased MPV level had a significantly 
shorter 5-year OS than patients with MPV > 9.1 fL (68.1% vs. 83.1%, 
p = 0.007) [19].
Evaluation of various hematological indices in patients with advanced 
non-small cell lung cancer (NSCLC) showed that MPV was 
significantly decreased in the NSCLC group compared with the control 
group. However, the PLT was significantly increased in the NSCLC 
group. Consequently, the MPV/PLT ratio was also decreased in the 
NSCLC group and it influenced OS, which was significantly shorter 
in the group with a low MPV/PC ratio (10.3 months vs. 14.5 months, 
p = 0.0245). Multivariate analysis confirmed that a low MPV/PC 
ratio was an independent unfavorable predictive factor for OS [20]. 
Furthermore, in locally advanced (stage IIIA/B) inoperable NSCLC 
MPV, as well as PLT and ECOG performance score were found as 
the most significant independent factors affecting survival (p < 0.001, 
p = 0.008, and, p = 0.034, respectively) [21]. Whereas, in epidermal 
growth factor receptor (EGFR) mutant lung adenocarcinoma, the 
MPV level not only influence prognosis but also predict the outcome 
of EGFR tyrosine kinase inhibitor (TKI) therapy. In this type of 
cancer, high MPV was significantly associated with shorter PFS – 
8.2 months in contrast to 14.7 months in low MPV-level group (p = 
0.0137). Interestingly, MPV was significantly increased in patients 
with smoking history. The EGFR–TKI therapy influenced MPV level. 
That parameter was decreased in group of patients after treatment, 
and the mean difference between pretreatment and posttreatment 
was 0.51 (95% confidence interval [CI] 0.38 ± 0.63, p < 0.001, paired 
t-test) [22].
Likewise, in patients with invasive breast cancer, pretreatment MPV 
levels were significantly higher than in healthy controls (8.65 fL vs. 
8.34 fL, p = 0.002). Moreover, high MPV levels significantly correlated 
with clinicopathologic parameters, such as distant metastasis 
(p = 0.039), primary tumor size (p = 0.042), and the tumor-node-
metastasis (TNM) stages (p = 0.035). Patients with MPV > 8.45 fL 
had significantly shorter OS compared to group with lower MPV level. 
The multivariate Cox proportional hazard models survival analysis 
demonstrated that MPV level was significant independent prognostic 
factors (p = 0.035, hazard ratio [HR] 1.86, 95% CI = 1.06–3.25) [23].
The diagnostic role of MPV in thyroid cancer has been confirmed 
in several researches. Baldane et al. [24] showed that preoperative 
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MPV levels in patients with papillary thyroid carcinoma were found to 
be significantly higher in comparison with benign goiter patients and 
healthy controls (8.05 fL vs. 7.57 fL/7.36 fL, p = 0.001). After surgical 
treatment of carcinoma, a significant decrease in MPV levels was 
seen. It decreased to 7.60 fL (p = 0.005), so the postoperative MPV 
levels of patients and healthy controls were comparable. The same 
association was confirmed by other studies, which showed that MPV 
was significantly higher in the group of patients with thyroid cancer 
than in the benign group [25, 26]. However, the prognostic role of 
MPV in this type of cancer has not yet been established.
Prognostic value of MPV in lymphoproliferative 
diseases
MPV seems to be significant prognostic factor not only in solid tumors 
but also in lymphoproliferative diseases. The prediction in these kinds 
of neoplasms is difficult and frequently require complicated analysis, 
including immunological, biochemical, and cytogenetic parameters.
Diffuse large B-cell lymphoma (DLBCL) is the most common type of 
non-Hodgkin lymphoma (NHL), accounting for 25% of all NHL cases 
in adults. In most cases, it presents an aggressive clinical course. 
The International Prognostic Index (IPI) score is used for prognosis; 
however, in significant percentage of cases, the course is unfavorable 
despite the low-risk index. Meanwhile, recent studies proved that in 
DLBCL patients receiving R-CHOP (rituximab, cyclophosphamide, 
doxorubicin, vincristine, and prednisone) chemotherapy, low MPV 
level is related to worse outcome. According to the study of Zhou 
et al. [27], the 2-year PFS rate is significantly longer in patients with 
MPV >9.1 fL compared to group with lower MPV level (84.0% vs. 
60.6%, p = 0.003). Moreover, the 2-years OS rate in those groups 
was 87.9% and 70.4%, respectively (p = 0.03). Univariate Cox 
regression analysis showed that low MPV (<9.1 fL) was independent 
prognostic factors for OS (p = 0.038) and PFS (p = 0.008). Multivariate 
analysis that included all the parameters having a p value of <0.05 
in the univariate analysis revealed that low MPV was independently 
associated with shorter OS (HR =0.588, 95% CI = 0.322–0.876, p = 
0.045) and PFS (HR = 0.456, 95% CI = 0.251–0.829, p = 0.010) [27].
Decreased MPV is also associated with the risk of venous 
thromboembolism (VTE) and increased mortality in patients treated 
for DLBCL. VTE is a frequent complication in patients with cancer 
and is associated with increased morbidity and mortality. The study 
of Rupa-Matysek et al. [28] showed that pre-chemotherapy MPV 
values were reduced in the patients with DLBC who developed VTE 
compared with those who did not. In univariate analysis, MPV ≤10th 
percentile was associated with VTE occurrence, in contrast to age, 
male gender, platelet count, Ki-67 index, DLBCL subclassification, 
advanced stage presence of constitutional symptoms, high and high-
intermediate IPI, and VTE risk. Whereas, patients with MPV >10th 
percentile had statistically significantly longer VTE-free survival than 
patients with lower MPV. Moreover, an estimated 3.5-year survival 
was 78% in patients without VTE occurrence and 55% in those who 
developed VTE and the probability of survival was higher in the 
patients with pre-chemotherapy high MPV compared with those with 
lower MPV (p = 0.0021) [28].
In patients diagnosed with Hodgkin lymphoma (HL), pre-chemotherapy 
MPV value cannot be used as a predictive marker for response. 
However, like in DLBCL, it may represent a useful prognostic marker 
for a significant VTE risk especially when incorporated into VTE 
risk assessment models. The study on patients with diagnosed HL 
proved that pre-chemotherapy values of MPV were significantly 
lower in the patients who developed VTE during follow-up (median 
6.9 fL) in comparison to the patients without VTE (median 7.2 fL, 
p = 0.034). Patients with baseline MPV 6.8 fL or below more often 
developed VTE compared to patients with higher MPV values (19% 
vs. 5.5%, p = 0.0244). Of the HL patients, in both the univariate and 
multivariate models, the patients with baseline low MPV levels had 
an above twofold increased risk of VTE development [29].
There are also reports about the prognostic role of platelet 
parameters in acute lymphoblastic leukemia (ALL) in pediatric 
patients [30, 31]. ALL is the most common type of cancer-affecting 
children, unfortunately, approximately 10% of young patients never 
achieve complete remission [32, 33]. In the study of Huang et al. [30], 
PLT, MPV, and PCT levels were found to be lower in the ALL group 
than in the normal and ALL complete remission induced groups (p 
< 0.05). Although in other research, the MPV was larger in patients 
with leukemia (mean ± SD: 8.615 ± 1.59 fL) than in controls group 
(mean ± SD: 8.355 ± 1.11 fL) at diagnosis, but it was statistically not 
significant between the two groups (p = 0.36). Authors suggested that 
the cause of this was probably dysplastic platelets in the leukemia 
group [31].
The clinical and prognostic significance of MPV was reported also 
in patients with primary (PMF) and secondary myelofibrosis (SMF). 
In these diseases, elevated MPV was associated with worse clinical 
outcome, including lower platelets (p = 0.016), higher white blood 
cells (p = 0.015), higher percentage of circulatory blasts (p = 0.009), 
higher lactate dehydrogenase (p = 0.011), larger spleen size (p = 
0.014), and higher Dynamic International Prognostic Score (DIPS) 
category (p = 0.027). Higher MPV was univariately associated with 
inferior OS in the whole cohort (HR = 3.82, p = 0.006) [34].
Conclusions
This review summarizes the most important studies on the impact of 
MPV levels on outcome and prognosis in different types of cancer 
conducted in recent years. In summary, MPV levels have a significant 
impact on the length of PFS and OS in many types of solid tumors, 
and also affect the prognosis in some lymphoproliferative diseases. 
However, the effect is not unitary and depends on the type of cancer. 
Moreover, MPV cutoff has not been fully validated so far, and 
standardization is essential to properly use MPV in clinical practice. 
Further studies are necessary to consider the use of affordable and 
accessible laboratory test such as MPV level as a prognostic factor. 
Moreover, the MPV cutoff level has not been fully validated so far and 
standardization is a major need.
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